Combined heat, targeted therapy and immunotherapy for liver cancer
Part of Cancer clinical trials.
This study tests a combined treatment using heat (thermal therapy), targeted drugs, and immunotherapy to shrink liver tumors that cannot be surgically removed. It aims to find out if this combination is safe and effective for people with intermediate or advanced liver cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with liver cancer that cannot be removed with surgery and is at an intermediate or advanced stage.
- You have not had any previous chemotherapy, targeted therapy, or immunotherapy for this cancer.
- The main tumor you will treat is 5 centimeters or smaller and can be seen on imaging scans.
- Your liver function is good (Child-Pugh score of 7 or less) and you are able to care for yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments—radiation therapy (SBRT), an immunotherapy drug (camrelizumab), and a targeted therapy (apatinib)—to see if they can shrink liver cancer enough to make surgery possible. It is for people whose liver cancer cannot be removed right now.
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
This trial tests a heat-based treatment for liver cancer tumors that uses multiple methods to destroy cancer cells. It may help people with liver tumors that haven't spread and who are healthy enough for treatment.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This trial tests whether adding a liver-directed treatment to standard systemic therapy can improve outcomes for people with liver cancer that cannot be removed. It may help shrink tumors or slow the disease while on current treatment.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
Hear when a new Unresectable Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.